Related Experiment Videos
Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension
1Department of Cardiovascular Medicine, Electric Power General Hospital, Beijing.
Insights
Perindopril and metoprolol effectively reduce left ventricular hypertrophy (LVH) in hypertensive patients. Perindopril demonstrated superior efficacy in LVH regression compared to metoprolol over 8 weeks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Left ventricular hypertrophy (LVH) is a common complication of essential hypertension.
- Effective antihypertensive treatment is crucial for managing LVH and improving cardiac function.
Purpose of the Study:
- To compare the effects of perindopril and metoprolol on LVH regression and diastolic function in patients with essential hypertension.
- To evaluate the efficacy of perindopril versus metoprolol in reversing LVH.
Main Methods:
- A randomized study involving 47 essential hypertensive patients with LVH.
- Patients received either perindopril (4-8 mg daily) or metoprolol (25-62.5 mg twice daily) for 8 weeks.
- Echocardiography was used to assess left ventricular mass index (LVMI) and function before and after treatment.
Main Results:
- Both perindopril and metoprolol significantly reduced LVMI after 8 weeks of treatment.
- Perindopril showed a more rapid and pronounced reduction in LVMI compared to metoprolol.
- LV diastolic function, indicated by E/A ratio, significantly improved in both groups, while systolic function remained unchanged.
Conclusions:
- Antihypertensive treatment with perindopril and metoprolol effectively reduces LVH and improves diastolic function.
- Perindopril is more effective than metoprolol in regressing left ventricular hypertrophy in hypertensive patients.
Abstract:
The effects of perindopril and metoprolol on left ventricular hypertrophy (LVH) and function were studied in 47 essential hypertensive patients with LVH. Previous antihypertensive drugs were discontinued for at least 2 weeks, after which patients were randomly divided into 2 groups. 25 subjects were treated with perindopril 4 to 8 mg once daily in the morning (Group A) and 22 subjects with metoprolol 25 to 62.5 mg twice daily (Group B). The subjects were evaluated before and after 4 and 8 weeks of treatment by use of echocardiography. Before treatment LV mass indexes (LVMI) of two groups were respectively 143.2 +/- 21.3 g/m2 and 140.6 +/- 23.7 g/m2 (P > 0.05). In Group A, reduction of LVMI occurred after 4 weeks of treatment, and more pronounced after 8 weeks (from 143.2 +/- 21.3 g/m2 to 126.6 +/- 15.3 g/m2, P < 0.001), whereas reduction of LVMI occurred only after 8 weeks in Group B (from 140.6 +/- 23.7 g/m2 to 133.4 +/- 13.2 g/m2, P < 0.001). In addition, there was a significant (P < 0.05) difference in LVMI between the two groups after 8 weeks. LV systolic function remained unchanged, whereas E/A increased significantly (P < 0.001) in two groups after 8 weeks. In conclusion, antihypertensive treatment with perindopril and metoprolol induced a significant regression of LVH associated with improvement in LV diastolic performance. Perindopril, compared with metoprolol, was more effective in reversing LVH.